Announcements
Expression of concern regarding paper by Park et al, published on 25 June 2015: “Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015”, Euro Surveill. 2015;20(25):pii=21169. It has been brought to our attention that some of the authors may not have been informed about the content of the above paper. There is a lack of clarity regarding rights to use the data. The editorial team are investigating what action needs to be taken.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance


In this issue


Home Eurosurveillance Edition  2016: Volume 21/ Issue 8 Article 4
Back to Table of Contents
Previous Download (pdf)
Next

Eurosurveillance, Volume 21, Issue 8, 25 February 2016
News
Eurosurveillance editorial team: WHO recommendations on the composition of the 2016/17 influenza virus vaccines in the northern hemisphere

+ Author affiliations


Citation style for this article: Eurosurveillance editorial team. WHO recommendations on the composition of the 2016/17 influenza virus vaccines in the northern hemisphere. Euro Surveill. 2016;21(8):pii=30147. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2016.21.8.30147


On 25 February 2016, the World Health Organization (WHO) published recommendations on the composition of the trivalent and quadrivalent vaccines for the 2016/17 northern hemisphere influenza season [1]. The recommendations for the influenza A(H1N1)pdm09 strain remained the same as in the previous year while the recommended strains for influenza A(H3N2) and B viruses have changed from those recommended in 2015/16. WHO recommends that trivalent influenza vaccines should contain the following:

  • an A/California/7/2009 (H1N1)pdm09-like virus;

  • an A/Hong Kong/4801/2014 (H3N2)-like virus;

  • a B/Brisbane/60/2008-like virus.

For the quadrivalent influenza vaccines which contain two influenza B viruses, the WHO recommends that the above three viruses plus a B/Phuket/3073/2013-like virus be used.

As in previous years, national or regional authorities approve the composition and formulation of vaccines used in each country and are responsible for making recommendations regarding the use of the vaccine.

For more information, read here



References

  1. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2016-2017 northern hemisphere influenza season. Geneva: WHO. Feb 2016. Available from:http://www.who.int/influenza/vaccines/virus/recommendations/201502_recommendation.pdf?ua=1



Back to Table of Contents
Previous Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.